Abstract
Non-Diagnostic (ND) biopsies are occasionally encountered during the investigation
of soft tissue sarcoma. We performed a retrospective review of all ND soft tissue
biopsies discussed at our regional Multi-Disciplinary Team (MDT) meeting between 2004
& 2014 with the aim of establishing the incidence of ND biopsies, identifying predictive
factors for repeat biopsies and evaluating the effectiveness of MDT decisions. We
identified 80 ND out of 3233 biopsies. Diagnostic Yield (DY) was 97.5%, 76.0% and
77.8% for the first, second and third successive biopsy respectively. With an MDT
approach utilising radiological and clinical information, the diagnostic success rate
achieved was 98.5%, 82.0% and 77.8% for the first, second and third biopsies respectively.
Malignant tumours (sarcoma & carcinoma) were 19 times more likely to undergo an increasing
number of biopsies compared to benign lesions (p < 0.01), while repeat biopsies were
less useful for suspected benign lesion. Although a repeat biopsy was only performed
in 63% of cases, there were no patients originally diagnosed with a benign lesion
that re-presented with the same lesion subsequently being malignant throughout the
study period. Our study shows that a specialist MDT approach leads to high diagnostic
rates and is a safe and effective method of preventing unnecessary, repeat biopsies
where the initial biopsy is ND.
Keywords
Abbreviations:
ND (Non-Diagnostic), MDT (Multi-Disciplinary Team), STS (Soft Tissue Sarcoma(s)), CNB (Core Needle Biopsy), UL (Upper Limb), LL (Lower Limb), Ca (Carcinoma), BL (Benign Lesion(s)), DY (Diagnostic Yield), DSR (Diagnosctic Success Rate), pCNB (Percutaneous Core Needle Biopsy)To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Surgical OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- ([Available from:)2010
- UK guidelines for the management of soft tissue sarcomas.Clin Sarcoma Res. 2016; 6: 20
- The hazards of the biopsy, revisited. Members of the Musculoskeletal Tumor Society.J Bone Joint Surg Am. 1996; 78: 656-663
- Accuracy of CT-guided needle biopsy of musculoskeletal neoplasms.AJR Am J Roentgenol. 1998; 171: 759-762
- Comparison between preoperative biopsy and post-excision histology results in sarcoma: experience at Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa.S Afr J Surg. 2014; 52: 45-48
- Accuracy of CT-guided biopsies in 359 patients with musculoskeletal lesions.Skeletal Radiol. 2002; 31: 349-353
- Computed tomography-guided core needle biopsy versus incisional biopsy in diagnosing musculoskeletal lesions.J Orthop Surg. 2013; 21: 204-208
- Are biopsy tracts a concern for seeding and local recurrence in sarcomas?.Clin Orthop Relat Res. 2017; 475: 511-518
- Sampling modality influences the predictive value of grading in adult soft tissue extremity sarcomas.Arch Pathol Lab Med. 2013; 137: 1774-1779
- Accurate diagnosis of musculoskeletal lesions by core needle biopsy.J Surg Oncol. 2006; 94: 21-27
- Revisiting CT-guided percutaneous core needle biopsy of musculoskeletal lesions: contributors to biopsy success.AJR Am J Roentgenol. 2011; 197: 457-461
- Percutaneous core needle biopsy versus open biopsy in diagnostics of bone and soft tissue sarcoma: a retrospective study.Eur J Med Res. 2012; 17: 29
- Image guided core needle biopsy of musculoskeletal lesions: are nondiagnostic results clinically useful?.Clin Orthop Relat Res. 2013; 471: 3601-3609
- CT-guided needle biopsy for musculoskeletal lesions.Arch Orthop Trauma Surg. 2010; 130: 699-703
- Analysis of nondiagnostic results after image-guided needle biopsies of musculoskeletal lesions.Clin Orthop Relat Res. 2010; 468: 3103-3111
- Journal club: utility of repeat core needle biopsy of musculoskeletal lesions with initially nondiagnostic findings.AJR Am J Roentgenol. 2017; 208: 609-616
- A Multidisciplinary Team Approach Is Highly Effective in the Management of Nondiagnostic Bone Tumour Biopsies: A 10-Year Retrospective Review at a Specialist Sarcoma Unit.Sarcoma. 2022; 2022: 7700365
- A daily diagnostic multidisciplinary meeting to reduce time to definitive diagnosis in the context of primary bone and soft tissue sarcoma.J Multidiscip Healthc. 2021; 14: 115-123
- Computed tomography-guided core needle biopsy for bone and soft tissue tumors.Isr Med Assoc J. 2003; 5: 28-30
- Small musculoskeletal soft-tissue lesions: US-guided core needle biopsy--comparative study of diagnostic yields according to lesion size.Radiology. 2016; 278: 156-163
- [Diagnostic value of ultrasound-guided core needle biopsy for soft tissue tumors].Zhonghua Bing Li Xue Za Zhi. 2013; 42: 158-162
- CT-guided percutaneous core needle biopsy in deep seated musculoskeletal lesions: a prospective study of 128 cases.Skeletal Radiol. 2006; 35: 138-143
- Bone and soft-tissue lesions: what factors affect diagnostic yield of image-guided core-needle biopsy?.Radiology. 2008; 248: 962-970
- Diagnostic value and accuracy of imprint cytology evaluation during image-guided core needle biopsies: review of our experience at a large academic center.Diagn Cytopathol. 2015; 43: 773-779
- Surgical biopsy with intra-operative frozen section. An accurate and cost-effective method for diagnosis of musculoskeletal sarcomas.J Bone Joint Surg Br. 2006; 88: 1207-1211
- Initial CT-guided needle biopsy of extremity skeletal lesions: diagnostic performance and experience of a tertiary musculoskeletal center.Eur J Radiol. 2014; 83: 360-365
Article info
Publication history
Published online: February 09, 2023
Accepted:
February 8,
2023
Received in revised form:
January 21,
2023
Received:
October 28,
2022
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2023 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
